Letairis is a brand-name medication whose active ingredient is ambrisentan. It belongs to the class of endothelin receptor antagonists and is used to treat pulmonary arterial hypertension (PAH), a serious condition affecting the heart and blood vessels. Available as a pill in strengths of 5 mg and 10 mg, Letairis is a prescription-only product in Hong Kong and is regulated by the Hong Kong Department of Health in alignment with international standards such as those set by the U.S. Food and Drug Administration (FDA).
Ambrisentan blocks the endothelin-A (ETA) receptors on the smooth muscle cells that line blood vessels. Endothelin-1 is a potent vasoconstrictor; when it binds to ETA receptors, the vessels narrow and pulmonary arterial pressure rises. By antagonizing these receptors, Letairis promotes vessel relaxation, reduces pulmonary arterial pressure, and improves exercise capacity in patients with PAH. The drug is well absorbed after oral administration, reaches peak plasma concentrations within 2-3 hours, and has a half-life of approximately 15 hours, supporting once-daily dosing.
Letairis is approved by the FDA and recognized by the Hong Kong regulatory authorities for the treatment of pulmonary arterial hypertension (PAH) in adults. PAH is characterized by high blood pressure in the arteries that carry blood from the heart to the lungs, leading to shortness of breath, fatigue, and, if untreated, right-heart failure. Letairis is indicated for patients with WHO functional class II or III who can benefit from improved hemodynamics and exercise tolerance.
Current peer-reviewed literature does not support any off-label indications for ambrisentan that meet the evidence threshold required for inclusion. Consequently, this section is omitted.
Absolute contraindications
Known hypersensitivity to ambrisentan or any tablet components
Pregnancy (ambrisentan is classified as a pregnancy-category X drug)
Severe hepatic impairment (Child-Pugh C)
Relative contraindications / cautions
Mild to moderate hepatic dysfunction (Child-Pugh A or B) - requires liver-function monitoring
Anemia or low baseline hemoglobin - periodic blood-count assessment recommended
Use of potent CYP3A4 inducers (e.g., rifampin, carbamazepine) - may reduce efficacy
Women of childbearing potential not using effective contraception
Special populations such as the elderly or patients with renal impairment do not require dose adjustment solely based on age or kidney function, but clinical judgment remains essential.
These events are typically transient and may lessen with continued therapy. Patients should report persistent or worsening edema to their healthcare provider.
If signs of liver injury (e.g., jaundice, dark urine) develop, Letairis should be discontinued and medical evaluation performed promptly.
Major interactions
CYP3A4 inducers (rifampin, carbamazepine, phenytoin) - markedly reduce ambrisentan plasma levels, potentially diminishing therapeutic effect. Co-administration is contraindicated.
Contraceptive hormonal agents - ambrisentan may reduce efficacy of combined oral contraceptives; an additional non-hormonal method is advised.
Moderate interactions
Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) - may increase ambrisentan exposure; dose adjustment is not routinely recommended, but clinicians should monitor for adverse effects.
Standard dosing
Initiate therapy with 5 mg once daily.
If tolerated and additional clinical benefit is needed, the dose may be increased to 10 mg once daily.
Special populations
Hepatic impairment: Start with 5 mg; avoid exceeding 5 mg in Child-Pugh B.
Pregnancy: Must not be used. Effective contraception is required for women of childbearing potential.
Administration tips
Swallow the tablet whole with a glass of water.
Do not crush, split, or chew the tablet unless instructed by a pharmacist.
Store tablets at room temperature, away from excess heat, moisture, and direct sunlight.
Missed dose
Take the missed dose as soon as remembered unless it is near the time of the next scheduled dose. Do not double up.
Overdose
Symptoms may include severe hypotension, dizziness, and hepatic dysfunction. Seek emergency medical care; supportive measures are the primary treatment.
Discontinuation
Letairis does not require tapering; however, abrupt cessation should be discussed with a healthcare provider, especially if the patient is stable on therapy.
This article provides educational information about Letairis and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. Letairis may be taken with or without food, as food does not significantly alter its absorption.
Report the edema to your healthcare provider; they may adjust the dose or add a diuretic to manage fluid retention.
Combined hormonal contraceptives may have reduced effectiveness when used with Letairis. An additional non-hormonal method, such as a copper IUD, is recommended.
Baseline testing is required, followed by assessments at 1, 3, and 6 months, then periodically as determined by your clinician.
Renal impairment does not typically require dose adjustment for Letairis, but your provider will consider overall health status.
Yes, but keep the medication in its original labeled container and carry a copy of the prescription to satisfy customs or airline security checks.
Letairis selectively blocks the ETA receptor, whereas some alternatives block both ETA and ETB receptors; this selectivity can affect side-effect profiles.
Acetaminophen does not have a known interaction, but non-steroidal anti-inflammatory drugs (NSAIDs) may increase fluid retention; discuss use with your provider.
Clinical trials showed measurable improvements in exercise capacity within 12 weeks, though individual response times vary.
Do not use them. Return the medication to a pharmacy take-back program or follow local disposal guidelines.
